Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 16/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9104926 | 0.92 | PDE10A (0.59) | PDE10AMEN1LMNAMAPTKMT2A | |
| SCHEMBL9104863 | 0.91 | PDE10A (0.74) | PDE10AMAPTPKM | |
| SCHEMBL9118417 | 0.91 | PDE10A (0.58) | PDE10ACYP1A2CYP2C19 | |
| SCHEMBL9107093 | 0.91 | PDE10A (0.58) | PDE10ACYP1A2CYP2C19KDM4EMEN1 | |
| SCHEMBL9904136 | 0.90 | PDE10A (0.63) | PDE10AMAPTPKM | |
| SCHEMBL9107079 | 0.90 | PDE10A (0.63) | PDE10AMAPTPKM | |
| SCHEMBL9899135 | 0.89 | PDE10A (0.60) | PDE10APKM | |
| SCHEMBL9904774 | 0.88 | PDE10A (0.69) | PDE10A | |
| SCHEMBL9107369 | 0.87 | PDE10A (0.60) | PDE10A | |
| SCHEMBL9904191 | 0.86 | PDE10A (0.55) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649070-B1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-09-17 | — | — | EP | claimed |
| EP-2649070-A1 | TRIAZOLOPYRIDINE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-16 | — | — | EP | claimed |
| US-8349824-B2 | Triazolopyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | claimed |
| WO-2012076430-A1 | TRIAZOLOPYRIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-14 | — | — | WO | claimed |
| US-20120142665-A1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-07 | — | — | US | claimed |
| US-20260076950-A1 | USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME | NOEMA PHARMA AG (CH) | 2026-03-19 | — | — | US | disclosed |
| US-12544364-B2 | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome | NOEMA PHARMA AG (CH) | 2026-02-10 | — | — | US | disclosed |
| US-20240390339-A1 | USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME | NOEMA PHARMA AG (CH) | 2024-11-28 | — | — | US | disclosed |
| US-11883385-B2 | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome | NOEMA PHARMA AG (CH) | 2024-01-30 | — | — | US | disclosed |
| EP-4284381-A1 | METHODS FOR THE TREATMENT OF CHILDHOOD-ONSET FLUENCY DISORDER | Noema Pharma AG (CH) | 2023-12-06 | — | — | EP | disclosed |
| CN-117157077-A | Methods of treating childhood onset fluency disorders | 诺埃玛制药公司 | 2023-12-01 | — | — | CN | disclosed |
| US-20230381193-A1 | METHODS FOR THE TREATMENT OF CHILDHOOD-ONSET FLUENCY DISORDER | NOEMA PHARMA AG (CH) | 2023-11-30 | — | — | US | disclosed |
| US-8349824-B2 | Triazolopyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349824-B2 | Triazolopyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349824-B2 | Triazolopyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| WO-2012076430-A1 | TRIAZOLOPYRIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076430-A1 | TRIAZOLOPYRIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142665-A1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120142665-A1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120142665-A1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11883385-B2 | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome | PDE2A, PDE3A, PDE5A | PDE10A 4/4885CYP1A2 1074/4885CYP2C19 455/4885 |
| US-20240390339-A1 | USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME | PDE2A, PDE3A, PDE5A | PDE10A 4/4885CYP1A2 1074/4885CYP2C19 455/4885 |
| US-12544364-B2 | Use of a phosphodiesterase 10 inhibitor for the treatment of tourette syndrome | PDE10A, PDE11A, PDE1A | PDE10A 1/4885CYP1A2 703/4885CYP2C19 342/4885 |
| US-20120142665-A1 | TRIAZOLOPYRIDINE COMPOUNDS | PDE5A, PDE3A, PDE3B | PDE10A 7/4885CYP1A2 134/4885CYP2C19 87/4885 |
| US-20230381193-A1 | METHODS FOR THE TREATMENT OF CHILDHOOD-ONSET FLUENCY DISORDER | PDE10A, PDE4A, PDE7B | PDE10A 1/4885CYP1A2 959/4885CYP2C19 1607/4885 |
| US-20260076950-A1 | USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME | PDE10A, PDE11A, PDE3A | PDE10A 1/4885CYP1A2 1056/4885CYP2C19 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.